Hepatitis News : Hepatitis B Vaccine Inventor Wills Nearly $50M to Research
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis News » February 2014


emailprint

February 6, 2014

Hepatitis B Vaccine Inventor Wills Nearly $50M to Research

Sir Ken Murray, the late scientist who helped develop the first vaccine against the hepatitis B virus (HBV), has posthumously left £30 million (nearly $50 million) to a charity he founded at Edinburgh University, the Daily Record reports. The 82-year-old professor died in 2013. Murray worked at the university for more than 30 years and was one of its first researchers in genetic engineering. His will reveals his estate was worth nearly £45 million at the time of his death, a fortune mostly built on royalties from the vaccine. His donation will help support the education of young scientists and fund research and facilities at the university, where he donated about £60 million (nearly $100 million) throughout his lifetime.

To read the article, click here.

Search: Ken Murray, Hepatitis B, vaccine, inventor, Ediniburgh University, Scotlant, donation


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Should Medicaid limit access to new hep C drugs?
Yes
No


Survey
Hepatitis C Reader Survey
HEP ON TWITTER
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.